Cargando…

Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS

OBJECTIVE: To examine the safety and tolerability as well as the preliminary efficacy of arimoclomol, a heat shock protein co-inducer that promotes nascent protein folding, in patients with rapidly progressive SOD1 amyotrophic lateral sclerosis (ALS). METHODS: This was a double-blind, placebo-contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benatar, Michael, Wuu, Joanne, Andersen, Peter M., Atassi, Nazem, David, William, Cudkowicz, Merit, Schoenfeld, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818014/ https://www.ncbi.nlm.nih.gov/pubmed/29367439 http://dx.doi.org/10.1212/WNL.0000000000004960

Ejemplares similares

Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatment
por: Mengel, Eugen, et al.
Publicado: (2021)

FYCO1 Increase and Effect of Arimoclomol–Treatment in Human VCP–Pathology
por: Guettsches, Anne-Katrin, et al.
Publicado: (2022)

Long‐term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS
por: Goutman, Stephen A., et al.
Publicado: (2018)

How common are ALS plateaus and reversals?
por: Bedlack, Richard S., et al.
Publicado: (2016)

The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase
por: Fog, Cathrine K., et al.
Publicado: (2018)

Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
por: Benatar, Michael, et al.
Publicado: (2022)

Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
por: Benatar, Michael, et al.
Publicado: (2022)

Urinary p75(ECD): A prognostic, disease progression, and pharmacodynamic biomarker in ALS
por: Shepheard, Stephanie R., et al.
Publicado: (2017)

Humoral response to neurofilaments and dipeptide repeats in ALS progression
por: Puentes, Fabiola, et al.
Publicado: (2021)

The heat-shock response co-inducer arimoclomol protects against retinal degeneration in rhodopsin retinitis pigmentosa
por: Parfitt, D A, et al.
Publicado: (2014)

Brain-penetrant heat shock protein amplifier arimoclomol enhances GCase activity in in vitro Gaucher disease models
por: Hettinghouse, Aubryanna, et al.
Publicado: (2018)

Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal
por: Benatar, Michael, et al.
Publicado: (2022)

Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [(11)C]-PBR28
por: Zürcher, Nicole R., et al.
Publicado: (2015)

Comparison between Golnar product and placebo in heavy menstrual bleeding: A double-blind randomized clinical trial
por: Yousefi, Fatemeh, et al.
Publicado: (2020)

Depending on the stress, histone deacetylase inhibitors act as heat shock protein co-inducers in motor neurons and potentiate arimoclomol, exerting neuroprotection through multiple mechanisms in ALS models
por: Kuta, Rachel, et al.
Publicado: (2020)

Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis
por: Alshikho, Mohamad J., et al.
Publicado: (2016)

Positron Emission Tomography Molecular Imaging Biomarkers for Amyotrophic Lateral Sclerosis
por: Chew, Sheena, et al.
Publicado: (2019)

Race/ethnicity, socioeconomic status, and ALS mortality in the United States
por: Roberts, Andrea L., et al.
Publicado: (2016)

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
por: Berry, James, et al.
Publicado: (2021)

Job-related formaldehyde exposure and ALS mortality in the USA
por: Roberts, Andrea L, et al.
Publicado: (2016)

Increased cerebral functional connectivity in ALS: A resting-state magnetoencephalography study
por: Proudfoot, Malcolm, et al.
Publicado: (2018)

Imaging of glia activation in people with primary lateral sclerosis
por: Paganoni, Sabrina, et al.
Publicado: (2017)

Caffeine Ingestion Enhances Repetition Velocity in Resistance Exercise: A Randomized, Crossover, Double-Blind Study Involving Control and Placebo Conditions
por: Grgic, Jozo, et al.
Publicado: (2020)

Profound Muscle Weakness and Pain after One Dose of Actonel
por: Badayan, Irina, et al.
Publicado: (2009)

FGF23, a novel muscle biomarker detected in the early stages of ALS
por: Si, Ying, et al.
Publicado: (2021)

ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
por: Lingor, Paul, et al.
Publicado: (2019)

An examination of wild-type SOD1 in modulating the toxicity and aggregation of ALS-associated mutant SOD1
por: Prudencio, Mercedes, et al.
Publicado: (2010)

Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk
por: Menke, Ricarda A L, et al.
Publicado: (2016)

Variation in aggregation propensities among ALS-associated variants of SOD1: Correlation to human disease
por: Prudencio, Mercedes, et al.
Publicado: (2009)

Cromolyn sodium delays disease onset and is neuroprotective in the SOD1(G93A) Mouse Model of amyotrophic lateral sclerosis
por: Granucci, Eric J., et al.
Publicado: (2019)

Rapid Progression of Sporadic ALS in a Patient Carrying SOD1 p.Gly13Arg Mutation
por: Kim, Myung-Jin, et al.
Publicado: (2016)

Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS)
por: Mandrioli, Jessica, et al.
Publicado: (2019)

Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity
por: Benatar, Michael, et al.
Publicado: (2022)

CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial
por: Apetauerova, Diana, et al.
Publicado: (2016)

A double-blind placebo needle for acupuncture research
por: Takakura, Nobuari, et al.
Publicado: (2007)

De novo mutations in SOD1 are a cause of ALS
por: Müller, Kathrin, et al.
Publicado: (2022)

Repeats expansions in ATXN2, NOP56, NIPA1 and ATXN1 are not associated with ALS in Africans
por: Nel, Melissa, et al.
Publicado: (2021)

Usefulness of a Double-Blind Placebo-Controlled Response Test to Demonstrate Rapid Onset Analgesia with Phenytoin 10% Cream in Polyneuropathy
por: Kopsky, David J, et al.
Publicado: (2020)

Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study
por: Thonhoff, Jason R., et al.
Publicado: (2018)

Microcurrent technology for rapid relief of sinus pain: a randomized, placebo‐controlled, double‐blinded clinical trial
por: Maul, Ximena A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jm8kn8mrbejhatb9fekbjp5bfm